Medicare AdvantageCoverageMedium impact
MA08.127e, Atezolizumab (Tecentriq®) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza TM)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Apr 1, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.127e for Atezolizumab (Tecentriq) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza) has been updated effective April 1, 2025. This policy update affects coverage and billing requirements for these cancer immunotherapy medications.
Action Required
By April 1, 2025: Billing team must review updated Medicare Advantage policy MA08.127e for Atezolizumab medications. Verify current prior authorization requirements and coverage criteria for Tecentriq and Tecentriq Hybreza before submitting claims. Access full policy details at the source URL to understand specific billing requirements.